Christophe De Block MD, PhDHead, Department of Endocrinology-Diabetology, University Hospital Antwerp; Full Professor, Endocrinology-Diabetology, University of Antwerp, University of Antwerp, Antwerp, Belgium
Christophe De Block studied medicine at the University of Antwerp, Belgium and graduated as M.D. magne cum laude. He is Head of the Department of Endocrinology-Diabetology & Metabolism at Antwerp University Hospital, Full Professor at the University of Antwerp, and Former President of the Diabetes Liga Belgium.
Prof. De Block’s main clinical and research interests are related to prediction and prevention of type 1 diabetes, autoimmune polyendocrine syndromes, and new treatment options for diabetes including incretin-based therapies. His latest field of interest focusses on the application of continuous glucose monitoring, functional insulin therapy, and sensor-augmented pump therapy.
Christophe De Block has received several scientific awards, including the Award of the Royal Academy of Medicine of Belgium for experimental investigations on autoimmune diseases, the Young Investigator’s Award of the Belgian Endocrine Society in 2005, and the Novo Nordisk Award for Diabetes 2015-2016. He has published more than 150 papers in international medical journals.
Christophe De Block is a member of the European Association for the Study of Diabetes (EASD), the American Diabetes Association (ADA), the Endocrine Society, the Belgian Diabetes Registry, and the Belgian Endocrine Society.
Dr. De Block reports consulting fees and honoraria for speaking for Abbott, AstraZeneca, Boehringer-Ingelheim, A. Menarini Diagnostics, Eli Lilly, Medtronic, Novo Nordisk, and Roche.